Food & Health
Law & Insurance
Nano & Biomaterials
Markets & Trends
Welcome to the
European Life Science Journal for international business
Get inspired by the entrepreneurs leading the way of tomorrow´s life science businesses !
Fusion protein boosts survival
Active Biotechs immunotoxin naptumomab estafenatox has doubled overall survival in renal cell cancer patients.A combination therapy of Active Biotechs fusion protein naptumomab estafenatox (ABR-217620), plus interferon-alpha, extended overall survival in a patient subgroup of the ANYARA Phase II/III study to 63.3 compared to 31.1 months in the interferon-alpha arm. The drug is a new class of f...
AstraZeneca buys Omthera
AstraZeneca has filled its pipeline with a Phase III fish oil cardioprotective drug, taking over Omthera Pharmaceuticals for $443m.The British-Swedish drug giant will pay Omthera $12.70 per share,...
Novo bags Xellia Pharmaceuticals
Danish Novo A/S has strengthened its pipeline of anti-infectives against multidrug resistant bugs by acquiring Norwegian Xellia Pharmaceuticals.The holding company of the Danish insulin producerNo...
BIO: debating value in Chicago
At the BIO International convention in Chicago, analysts have reported strong performance from the global biotech sector.They pointed out that there is an urgent need for the industry to demonstra...
Horizon teams up with AstraZeneca
AstraZeneca has exclusively licenced Horizon Discoverys kinase target programme.Horizon Discovery and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Hori...
Trial success for Lundbeck
In a thorough comparison, Lundbecks new antidepressant Brintellix shone brightly: On a system for rating depression patients performed better.Danish H. Lundbeck A/S reported on positive results fo...
AstraZeneca fails endpoint
AstraZenecas arthritis pill fostamatinib is proven inferior to competitor drugs in a late-stage clinical trial.While the first-in-class oral rheumatoid (RA) arthritis drug proved to be efficient a...
Clavis 2nd lead failed
Clavis Pharma has become a target for a take-over after its cancer drug delivery technology failed proof-of-concept for the second time.In November, US partner Clovis Oncology said it will termina...
British Shire plc has broadened its therapeutic scope to neonatology by the strategic acquisition of Swedish Premacure AB of Uppsala.
The privately held biotech company is running a dose finding, safety and efficacy Phase II programme for the most common cause of visual loss in childhood – the prevention of retinopathy of prematu...
Active Biotech raises €32.4m
SwedishActive Biotech has issued new shares to obtain money for its clinicalautoimmunity and cancer programmes. 0 false 21 18 pt 18 pt 0 0 false false false ...